Moderna, Inc. (NASDAQ: MRNA) is a commercial-stage biotechnology company created in 2010. As of early 2021, Moderna had 24 mRNA development programmes, with 13 of those in clinical trials. Infectious disease and oncology are among the therapeutic areas covered by the programmes.
The Company announced on February 3, 2022, that it would report the fourth quarter and full-year 2021 financial results on February 24, 2022.
Financial Highlights: Q3FY21 (ended on September 30, 2021)
(Source: Company Filing)
Valuation Methodology: EV/Sales Multiple based Relative Valuation
Analysis by Kalkine Group
The company reported decent performance in the Q3FY21 driven by sales of 208 million doses of the Covid-19 vaccine. Further the company expects to realize product sales between USD15 and USD18bn for FY2021 and plans to supply 700-800 million 100µg doses of its Covid-19 vaccine this fiscal year. However, Therefore, given its robust financials, new arrangements and expansions, current valuation, and risk associated, we recommend a "Buy" rating on the stock at the current market price of USD 147.95, February 16, 2022, at 01:51 PM ET.
1-Year Technical Price Chart (as on February 16, 2022, at 01:50 PM ET). Source: REFINITIV, Analysis by Kalkine Group
Technical Summary Analysis
Technical Indicators Defined: -
Support: A level where-in the stock prices tend to find support if they are falling, and downtrend may take a pause backed by demand or buying interest.
Resistance: A level where-in the stock prices tend to find resistance when they are rising, and uptrend may take a pause due to profit booking or selling interest.
Stop-loss: It is a level to protect further losses in case of unfavourable movement in the stock prices.
Note 1: The reference data in this report has been partly sourced from REFINITIV.
Note 2: Investment decision should be made depending on the investors' appetite on upside potential, risks, holding duration, and any previous holdings. Investors can consider exiting from the stock if the Target Price mentioned as per the valuation has been achieved and subject to the factors discussed above.